Novo’s lawsuit and FDA pressure hit compounded GLP‑1 pills and jolt obesity‑drug stocks
A US$49 knock-off Wegovy pill just handed Novo Nordisk a rare victory in its battle with compounded GLP‑1 drugs – and signalled that regulators and courts are closing in on the cut‑price obesity market that many portfolios now touch.
According to Reuters, Hims & Hers briefly offered a compounded version of Novo Nordisk’s Wegovy pill for US$49 a month, roughly US$100 below Novo’s own price.
The company abruptly pulled the product after the US Food and Drug Administration said it would move to restrict GLP‑1 ingredients in compounded drugs over safety, quality and legal concerns.
The US Department of Health and Human Services plans to refer Hims & Hers to the Department of Justice.
BNN Bloomberg reports that Novo has now sued Hims & Hers in Delaware, alleging that its compounded semaglutide pills and injections infringe Novo’s US patents and asking the court to permanently ban sales of those unapproved products while seeking damages.
Novo’s general counsel called the Hims launch a “tipping point” in the compounding debate.
On the other side, Hims labelled the suit a “blatant attack” on “millions of Americans who rely on compounded medications” and accused “Big Pharma” of weaponizing the courts to limit consumer choice.
Bloomberg adds that Novo argues Hims’ compounded semaglutide “knock‑offs” put patient health at risk and says its own drugs follow FDA manufacturing and safety rules.
Regulators appear to be siding with the originators.
CNBC reports that the FDA plans “decisive steps” against GLP‑1 compounding and warned it cannot verify the quality, safety or efficacy of such drugs, while also vowing to crack down on “misleading direct‑to‑consumer advertising” that suggests compounded products are equivalent to approved brands.
According to Reuters, FDA Commissioner Marty Makary said the agency will use all available enforcement tools to address unsubstantiated claims and related public‑health risks.
The market reaction underlines how material this is.
BNN Bloomberg reports that after Hims withdrew the pill and Novo filed its lawsuit, Novo’s shares climbed about 5 percent while Hims dropped roughly 20 percent, reversing some of the earlier damage when the US$49 pill was announced.
Bloomberg notes that Novo’s market value has already fallen from more than US$600bn in 2024 to about US$227bn amid “unprecedented price pressure,” even as obesity drugs remain central to its long‑term story.
